These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37395627)

  • 1. Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis.
    Mohamed MFH; Ward C; Beran A; Abdallah MA; Asemota J; Kelly CR
    J Clin Gastroenterol; 2024 Apr; 58(4):389-401. PubMed ID: 37395627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence.
    Johnson TM; Molina KC; Howard AH; Schwarz K; Allen L; Huang M; Bajrovic V; Miller MA
    Clin Infect Dis; 2022 May; 74(9):1572-1578. PubMed ID: 34665248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.
    Meschiari M; Cozzi-Lepri A; Cervo A; Granata G; Rogati C; Franceschini E; Casolari S; Tatarelli P; Giacobbe DR; Bassetti M; Pinna SM; De Rosa FG; Barchiesi F; Canovari B; Lorusso C; Russo G; Cenderello G; Cascio A; Petrosillo N; Mussini C
    Int J Infect Dis; 2023 Jun; 131():147-154. PubMed ID: 37030653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
    Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
    Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
    Salavert M; Cobo J; Pascual Á; Aragón B; Maratia S; Jiang Y; Aceituno S; Grau S
    Adv Ther; 2018 Nov; 35(11):1920-1934. PubMed ID: 30328061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.
    Akiyama S; Yamada A; Komaki Y; Komaki F; Micic D; Sakuraba A
    J Clin Gastroenterol; 2021 Jan; 55(1):43-51. PubMed ID: 32053529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent
    Alhifany AA; Almutairi AR; Almangour TA; Shahbar AN; Abraham I; Alessa M; Alnezary FS; Cheema E
    BMJ Open; 2019 Nov; 9(11):e031145. PubMed ID: 31699731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Association Reveals Protection against Recurrence of
    Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
    mSphere; 2020 May; 5(3):. PubMed ID: 32376702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
    Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
    Prabhu VS; Dubberke ER; Dorr MB; Elbasha E; Cossrow N; Jiang Y; Marcella S
    Clin Infect Dis; 2018 Jan; 66(3):355-362. PubMed ID: 29106516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
    Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
    Goldstein EJC; Citron DM; Gerding DN; Wilcox MH; Gabryelski L; Pedley A; Zeng Z; Dorr MB
    Clin Infect Dis; 2020 Aug; 71(4):1102-1105. PubMed ID: 31883370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live Biotherapeutic Products for the Prevention of Recurrent
    Pettit NN; Shaeer KM; Chahine EB
    Ann Pharmacother; 2024 Dec; 58(12):1204-1217. PubMed ID: 38546138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland.
    Oksi J; Aalto A; Säilä P; Partanen T; Anttila VJ; Mattila E
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1947-1952. PubMed ID: 31359254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
    Johnson S; Citron DM; Gerding DN; Wilcox MH; Goldstein EJC; Sambol SP; Best EL; Eves K; Jensen E; Dorr MB
    Clin Infect Dis; 2021 Nov; 73(9):e2616-e2624. PubMed ID: 32735653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bezlotoxumab for the Prevention of
    Chahine EB; Cho JC; Worley MV
    Consult Pharm; 2018 Feb; 33(2):89-97. PubMed ID: 29409575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
    Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
    Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.
    Yee KL; Kleijn HJ; Zajic S; Dorr MB; Wrishko RE
    J Pharmacokinet Pharmacodyn; 2020 Apr; 47(2):121-130. PubMed ID: 32048107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.